Literature DB >> 4143468

Cerebrovascular Moyamoya disease. IIIrd report--the study on the aging of the perforating branches and the possibility of collateral pathway.

N Kodama, J Suzuki.   

Abstract

Entities:  

Mesh:

Year:  1974        PMID: 4143468     DOI: 10.2176/nmc.14pt1.supplement_55

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


× No keyword cloud information.
  6 in total

1.  Factors influencing the development of Moyamoya phenomenon.

Authors:  K Takeuchi; M Hara; H Yokota; J Okada; K Akai
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

2.  A source of haemorrhage in adult patients with moyamoya disease: the significance of tributaries from the choroidal artery.

Authors:  K Irikura; Y Miyasaka; A Kurata; R Tanaka; K Fujii; K Yada; S Kan
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Minor head injury as cause and co-factor in the aetiology of stroke in childhood: a report of eight cases.

Authors:  M Kieslich; A Fiedler; C Heller; W Kreuz; G Jacobi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-07       Impact factor: 10.154

4.  Analysis of the angiographic findings in cases of childhood moyamoya disease.

Authors:  S Satoh; H Shibuya; Y Matsushima; S Suzuki
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

5.  Visualization of periventricular collaterals in moyamoya disease with flow-sensitive black-blood magnetic resonance angiography: preliminary experience.

Authors:  Takeshi Funaki; Yasutaka Fushimi; Jun C Takahashi; Yasushi Takagi; Yoshio Araki; Kazumichi Yoshida; Takayuki Kikuchi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

Review 6.  Current status of infarction in the basal ganglia-internal capsule due to mild head injury in children using PRISMA guidelines.

Authors:  Guangming Wang; Yongxin Luan; Lu Feng; Jinlu Yu
Journal:  Exp Ther Med       Date:  2019-12-12       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.